Eupraxia Pharmaceuticals Inc. Common Stock Cash Flow Conversion Efficiency
Eupraxia Pharmaceuticals Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) has a cash flow conversion efficiency ratio of -0.037x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.51 Million) by net assets ($123.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Eupraxia Pharmaceuticals Inc. Common Stock (2017–2024)
Cash flow conversion efficiency of Eupraxia Pharmaceuticals Inc. Common Stock from 2017 to 2024. This chart illustrates how Eupraxia Pharmaceuticals Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Eupraxia Pharmaceuticals Inc. Common Sto share price for real-time trading data and today's change.
Eupraxia Pharmaceuticals Inc. Common Stock Cash Flow Conversion Ratio Explained
Eupraxia Pharmaceuticals Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Eupraxia Pharmaceuticals Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eupraxia Pharmaceuticals Inc. Common Stock ranked by their cash flow conversion efficiency. Also see EPRX stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sanyou Corporation Limited
SHE:300932
|
N/A |
|
Jiangsu Flag Chemical Industry Co Ltd
SHE:300575
|
0.074x |
|
VIP Industries Limited
NSE:VIPIND
|
0.136x |
|
Shandong Xinjufeng Technology Packaging Co. Ltd. A
SHE:301296
|
N/A |
|
Viking Tech
TWO:3624
|
0.055x |
|
North American Financial 15
TO:FFN
|
0.060x |
|
K-Bro Linen Inc.
TO:KBL
|
0.031x |
|
eQ Oyj
HE:EQV1V
|
0.103x |
Annual Cash Flow Conversion Efficiency for Eupraxia Pharmaceuticals Inc. Common Stock (2017–2024)
The table below shows the annual cash flow conversion efficiency of Eupraxia Pharmaceuticals Inc. Common Stock from 2017 to 2024. Review EPRX free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $31.84 Million | $-29.99 Million | -0.942x | +95.95% |
| 2023-12-31 | $892.33K | $-20.75 Million | -23.252x | -1476.36% |
| 2022-12-31 | $9.76 Million | $-14.40 Million | -1.475x | -143.62% |
| 2021-12-31 | $19.12 Million | $-11.58 Million | -0.605x | -3348.52% |
| 2020-12-31 | $-21.66 Million | $-403.78K | 0.019x | -93.46% |
| 2019-12-31 | $-18.13 Million | $-5.17 Million | 0.285x | -60.80% |
| 2018-12-31 | $-11.44 Million | $-8.32 Million | 0.728x | +170.13% |
| 2017-12-31 | $5.11 Million | $-5.30 Million | -1.038x | -- |
About Eupraxia Pharmaceuticals Inc. Common Stock
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unm… Read more